High throughput (HTS) and high content screening (HCS) assays often utilize cell sources, which are not amenable to large-scale screening and can require extensive cell culture and processing prior to imaging. To overcome this hurdle, Hera and a commercial partner ArunA Biomedical, engineered human neural progenitors derived from stem cells with a non-viral vector encoding a GFP reporter gene using a selectable piggyBac™ gene editing system to produce hNP1 GFP+ cells. hNP1 reporter cells exhibit detectable dose dependent response to toxins tested, (cytotoxicity and cell migration) providing a sensitive, high throughput and high content amenable, cell based human neurotox assay platform.